Technion Ranked 31st in US for Patents

Technion ranked 31st in the world in the U.S. Academy of Inventors index

The Technion received approval for 65 patents in the U.S. in 2014, the most of any Israeli university.

The rankings list of the National Academy of Inventors, founded in the U.S. in 2010, ranks the Technion in 31st place in the list of universities around the world, based on the number of patents approved in the U.S. in 2014. The Technion, with 65 approved patents last year, ranks above well-known universities such as Yale, Duke, Rutgers, USC (University of Southern California) and Tokyo University, as well as all the other Israeli institutions that placed in the rankings: Tel Aviv University (43rd place), the Weizmann Institute (52nd place) and Hebrew University (73rd place). The top-ranked university is MIT, which advanced from second place in 2013, with 453 approved patents in 2014.

Benjamin Soffer, director of T3―Technion Technology Transfer Office

Benjamin Soffer, director of T3―Technion Technology Transfer Office

A few of the patents registered by the Technion and approved in 2014 are: medical scaffolding; a system for monitoring air passage in the lungs; a system for the rapid imaging of the macula; non-friction molecular engines; an innovative device for separating oxygen from air; silicon-air batteries; and assessment for the early diagnosis of growths in the large intestine.

Prof. Wayne D. Kaplan, Technion’s Executive Vice President for Research, congratulated the researchers, senior staff and students on this impressive achievement.

“The commercialization of inventions and the registering of patents are strategic goals for us, connected with strengthening the ties between academia and industry. The Technion invests significant resources in these matters, and the Technion’s patent registration department, headed by Ofir Alon, is doing wonderful work. We will continue to strive to translate research into finished technology and to bring inventions from the lab to the market.”

Benjamin Soffer, director of T3―Technion Technology Transfer Office, which houses the patent registration department, said that this impressive accomplishment is “an expression of the Technion’s tremendous openness to innovation and to the balance between the entrepreneurial spirit and excellence in academia and research. In the past few decades the Technion has been constantly increasing the entrepreneurial component in training students, with the intention that at the end of their studies the students will be equipped not only with scientific and engineering tools, but also with the managerial and entrepreneurial skills that will enable them to ‘invent their own workplace’ and not only to find jobs as salaried employees in existing companies.”

Technology made in Israel: enjoy the T3 2015 Profile

Technology made in Israel: enjoy the T3 2015 Profile

In many instances, the approval of a patent is the preliminary stage to the commercialization of technology or an invention. In the commercialization field, too, the Technion has made impressive strides: Within less than a decade, revenues from commercialization have jumped from $10.7 million annually (in 2008-2009) to over $30 million (2014-2015).

“It’s important to take into account that the Technion’s research budget, $135 million a year, is very low compared to the other universities and is only 8% of the MIT’s research budget. If the universities were ranked based on their revenues from commercialization relative to their research expenditures, the Technion would be in third place, behind Princeton and New York University,” said Soffer.

The Technion Technology Transfer (T³) office operated in the framework of the Technion Research & Development Foundation, and is responsible for the commercialization and protection of intellectual property developed by the Technion. One of the outstanding successes in this field is the commercialization of Azilect, a drug developed in cooperation with Teva Pharmaceuticals, based on research by professors Moussa Youdim and John Finberg. Sales of this drug top $400 million annually.

T3 manages holdings in some 50 active companies and over the past three years, the Technion’s portfolio companies have raised over $250 million in investment capital. These companies include Argo Medical Technologies (which develops exoskeletons to help the disabled to walk); Applied Immune Technologies (a drug development company specializing in T-Cell Receptor-Like, TCRL, antibodies); Accellta (media and cell cultures for the stem cell industry), Sealantis (tissue adhesive); Avraham Pharmaceuticals (drugs to slow the progression of Alzheimer’s and mild cognitive disorders), Corindus (robotics technology that enables cardiologists to perform remote catheterization), VibeSec (information security on web-based telephony), NanoSpun Technologies (smart fibers), ElMindA (imaging system for neuron network activity in the brain and treatment based on network stimulation) DigiFlex (products for the printing industry and industrial processes) and Regentis (gel for regenerating tissue).

The department is responsible, among other things, for the management of the Technion’s patent portfolio, which has over 780 applications for patent registration.

For the full list of the rankings: